pharmaceuticals-and-healthcare

EMEA (Europe, Middle East and Africa) Inactivated Vaccine Market Report 2017


Published On : Aug 2017

Category : Pharmaceutical

No. of Pages : 104 pages

  • $4000
  • $8000

SPECIFY YOUR RESEARCH NEED

  • Query Type :
  •  
Table of Contents

EMEA (Europe, Middle East and Africa) Inactivated Vaccine Market Report 2017
1 Inactivated Vaccine Overview
1.1 Product Overview and Scope of Inactivated Vaccine
1.2 Classification of Inactivated Vaccine
1.2.1 EMEA Inactivated Vaccine Market Size (Sales) Comparison by Type (2012-2022)
1.2.2 EMEA Inactivated Vaccine Market Size (Sales) Market Share by Type (Product Category) in 2016
1.2.3 Pediatrics
1.2.4 Adults
1.3 EMEA Inactivated Vaccine Market by Application/End Users
1.3.1 EMEA Inactivated Vaccine Sales (Volume) and Market Share Comparison by Application (2012-2022
1.3.2 Hospital
1.3.3 Medical Center
1.3.4 Others
1.4 EMEA Inactivated Vaccine Market by Region
1.4.1 EMEA Inactivated Vaccine Market Size (Value) Comparison by Region (2012-2022)
1.4.2 Europe Status and Prospect (2012-2022)
1.4.3 Middle East Status and Prospect (2012-2022)
1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Inactivated Vaccine (2012-2022)
1.5.1 EMEA Inactivated Vaccine Sales and Growth Rate (2012-2022)
1.5.2 EMEA Inactivated Vaccine Revenue and Growth Rate (2012-2022)

2 EMEA Inactivated Vaccine Competition by Manufacturers/Players/Suppliers, Region, Type and Application
2.1 EMEA Inactivated Vaccine Market Competition by Players/Manufacturers
2.1.1 EMEA Inactivated Vaccine Sales Volume and Market Share of Major Players (2012-2017)
2.1.2 EMEA Inactivated Vaccine Revenue and Share by Players (2012-2017)
2.1.3 EMEA Inactivated Vaccine Sale Price by Players (2012-2017)
2.2 EMEA Inactivated Vaccine (Volume and Value) by Type/Product Category
2.2.1 EMEA Inactivated Vaccine Sales and Market Share by Type (2012-2017)
2.2.2 EMEA Inactivated Vaccine Revenue and Market Share by Type (2012-2017)
2.2.3 EMEA Inactivated Vaccine Sale Price by Type (2012-2017)
2.3 EMEA Inactivated Vaccine (Volume) by Application
2.4 EMEA Inactivated Vaccine (Volume and Value) by Region
2.4.1 EMEA Inactivated Vaccine Sales and Market Share by Region (2012-2017)
2.4.2 EMEA Inactivated Vaccine Revenue and Market Share by Region (2012-2017)
2.4.3 EMEA Inactivated Vaccine Sales Price by Region (2012-2017)

3 Europe Inactivated Vaccine (Volume, Value and Sales Price), by Players, Countries, Type and Application
3.1 Europe Inactivated Vaccine Sales and Value (2012-2017)
3.1.1 Europe Inactivated Vaccine Sales Volume and Growth Rate (2012-2017)
3.1.2 Europe Inactivated Vaccine Revenue and Growth Rate (2012-2017)
3.2 Europe Inactivated Vaccine Sales and Market Share by Type
3.3 Europe Inactivated Vaccine Sales and Market Share by Application
3.4 Europe Inactivated Vaccine Sales Volume and Value (Revenue) by Countries
3.4.1 Europe Inactivated Vaccine Sales Volume by Countries (2012-2017)
3.4.2 Europe Inactivated Vaccine Revenue by Countries (2012-2017)
3.4.3 Germany Inactivated Vaccine Sales and Growth Rate (2012-2017)
3.4.4 France Inactivated Vaccine Sales and Growth Rate (2012-2017)
3.4.5 UK Inactivated Vaccine Sales and Growth Rate (2012-2017)
3.4.6 Russia Inactivated Vaccine Sales and Growth Rate (2012-2017)
3.4.7 Italy Inactivated Vaccine Sales and Growth Rate (2012-2017)
3.4.8 Benelux Inactivated Vaccine Sales and Growth Rate (2012-2017)

4 Middle East Inactivated Vaccine (Volume, Value and Sales Price), by Region, Type and Application
4.1 Middle East Inactivated Vaccine Sales and Value (2012-2017)
4.1.1 Middle East Inactivated Vaccine Sales Volume and Growth Rate (2012-2017)
4.1.2 Middle East Inactivated Vaccine Revenue and Growth Rate (2012-2017)
4.2 Middle East Inactivated Vaccine Sales and Market Share by Type
4.3 Middle East Inactivated Vaccine Sales and Market Share by Application
4.4 Middle East Inactivated Vaccine Sales Volume and Value (Revenue) by Countries
4.4.1 Middle East Inactivated Vaccine Sales Volume by Countries (2012-2017)
4.4.2 Middle East Inactivated Vaccine Revenue by Countries (2012-2017)
4.4.3 Saudi Arabia Inactivated Vaccine Sales and Growth Rate (2012-2017)
4.4.4 Israel Inactivated Vaccine Sales and Growth Rate (2012-2017)
4.4.5 UAE Inactivated Vaccine Sales and Growth Rate (2012-2017)
4.4.6 Iran Inactivated Vaccine Sales and Growth Rate (2012-2017)

5 Africa Inactivated Vaccine (Volume, Value and Sales Price) by Players, Countries, Type and Application
5.1 Africa Inactivated Vaccine Sales and Value (2012-2017)
5.1.1 Africa Inactivated Vaccine Sales Volume and Growth Rate (2012-2017)
5.1.2 Africa Inactivated Vaccine Revenue and Growth Rate (2012-2017)
5.2 Africa Inactivated Vaccine Sales and Market Share by Type
5.3 Africa Inactivated Vaccine Sales and Market Share by Application
5.4 Africa Inactivated Vaccine Sales Volume and Value (Revenue) by Countries
5.4.1 Africa Inactivated Vaccine Sales Volume by Countries (2012-2017)
5.4.2 Africa Inactivated Vaccine Revenue by Countries (2012-2017)
5.4.3 South Africa Inactivated Vaccine Sales and Growth Rate (2012-2017)
5.4.4 Nigeria Inactivated Vaccine Sales and Growth Rate (2012-2017)
5.4.5 Egypt Inactivated Vaccine Sales and Growth Rate (2012-2017)
5.4.6 Algeria Inactivated Vaccine Sales and Growth Rate (2012-2017)

6 EMEA Inactivated Vaccine Manufacturers/Players Profiles and Sales Data
6.1 Astellas Pharma (Japan)
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Inactivated Vaccine Product Type, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Astellas Pharma (Japan) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 CSL Limited (Australia)
6.2.1 Company Basic Information, Manufacturing Base and Competitors
6.2.2 Inactivated Vaccine Product Type, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 CSL Limited (Australia) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 Emergent BioSolutions (U.S.)
6.3.1 Company Basic Information, Manufacturing Base and Competitors
6.3.2 Inactivated Vaccine Product Type, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Emergent BioSolutions (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 GlaxoSmithKline (U.K.)
6.4.1 Company Basic Information, Manufacturing Base and Competitors
6.4.2 Inactivated Vaccine Product Type, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 GlaxoSmithKline (U.K.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
6.5 Johnson & Johnson (U.S.)
6.5.1 Company Basic Information, Manufacturing Base and Competitors
6.5.2 Inactivated Vaccine Product Type, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Johnson & Johnson (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
6.5.4 Main Business/Business Overview
6.6 MedImmune (U.S.)
6.6.1 Company Basic Information, Manufacturing Base and Competitors
6.6.2 Inactivated Vaccine Product Type, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 MedImmune (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
6.6.4 Main Business/Business Overview
6.7 Merck & Co (U.S.)
6.7.1 Company Basic Information, Manufacturing Base and Competitors
6.7.2 Inactivated Vaccine Product Type, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Merck & Co (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
6.7.4 Main Business/Business Overview
6.8 Pfizer (U.S.)
6.8.1 Company Basic Information, Manufacturing Base and Competitors
6.8.2 Inactivated Vaccine Product Type, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Pfizer (U.S.) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
6.8.4 Main Business/Business Overview
6.9 Sanofi Pasteur (France)
6.9.1 Company Basic Information, Manufacturing Base and Competitors
6.9.2 Inactivated Vaccine Product Type, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 Sanofi Pasteur (France) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
6.9.4 Main Business/Business Overview
6.10 Serum Institute of India Pvt (India)
6.10.1 Company Basic Information, Manufacturing Base and Competitors
6.10.2 Inactivated Vaccine Product Type, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Serum Institute of India Pvt (India) Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
6.10.4 Main Business/Business Overview

7 Inactivated Vaccine Manufacturing Cost Analysis
7.1 Inactivated Vaccine Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Inactivated Vaccine

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Inactivated Vaccine Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Inactivated Vaccine Major Manufacturers in 2016
8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List

10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA Inactivated Vaccine Market Forecast (2017-2022)
11.1 EMEA Inactivated Vaccine Sales, Revenue and Price Forecast (2017-2022)
11.1.1 EMEA Inactivated Vaccine Sales and Growth Rate Forecast (2017-2022)
11.1.2 EMEA Inactivated Vaccine Revenue and Growth Rate Forecast (2017-2022)
11.1.3 EMEA Inactivated Vaccine Price and Trend Forecast (2017-2022)
11.2 EMEA Inactivated Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Inactivated Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Inactivated Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Inactivated Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Inactivated Vaccine Sales Forecast by Type (2017-2022)
11.7 EMEA Inactivated Vaccine Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer


Back To Top